SCOPUS 정보 검색 플랫폼

Volumn 24, Issue 11, 2011, Pages 31-35

Biobetters and the future biologics market: Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs

(1) Dinwoodie, Niall a

a Charles River (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; IMMUNE RESPONSE; PROCESS DEVELOPMENT;

EID: 83455255358 PISSN: 1542166X EISSN: 19391862 Source Type: Trade Journal
DOI: None Document Type: Article

Times cited : (3)

References (14)

1
- 83455260733
- EC Directive 2004/27/EC, amending Directive 2001/83/EC The Community Code Relating to Medicinal Products for Human Use, Brussels, March
- EC Directive 2004/27/EC, amending Directive 2001/83/EC The Community Code Relating to Medicinal Products for Human Use (Brussels, March 2004).
- (2004)

2
- 83455205161
- TGA News, 57, November
- TGA News, 57, November 2009.
- (2009)

3
- 80053560333
- Health Canada, Guidance for Sponsors, Ottowa, March
- Health Canada, Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (Ottowa, March 2010).
- (2010) Information and Submission Requirements for Subsequent Entry Biologics

4
- 84855478786
- MHLW, in Japanese
- MHLW, Guideline for the Quality, Safety and Effectiveness of Biosimilar Products (in Japanese) wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/2005I210304007.pdf.
- Guideline for the Quality, Safety and Effectiveness of Biosimilar Products

5
- 19044374719
- H. Schelleckens, Eur. J. Hosp. Pharm. 10, 243-247 (2004).
- (2004) Eur. J. Hosp. Pharm. , vol.10 , pp. 243-247
- Schelleckens, H.¹

6
- 77953339692
- EMA, London
- EMA, "Questions and Answers on the Withdrawl of the Marketing Authorization for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel" (London, 2008).
- (2008) Questions and Answers on the Withdrawl of the Marketing Authorization for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel

7
- 79952744875
- M. McCamish and G. Woollett, mAbs 3 (2), 212-220 (2011).
- (2011) MAbs , vol.3 , Issue.2 , pp. 212-220
- McCamish, M.¹ Woollett, G.²

8
- 70349589392
- Federal Trade Commission, Washington, DC, June
- Federal Trade Commission, "Emerging Health Care Issues: Follow-on Biologic Drug Competition" (Washington, DC, June 2009).
- (2009) Emerging Health Care Issues: Follow-on Biologic Drug Competition

9
- 34447503942
- J. Woodcock et al., Nat. Rev. Drug Disc. 6, 437-442 (2007).
- (2007) Nat. Rev. Drug Disc. , vol.6 , pp. 437-442
- Woodcock, J.¹

10
- 83455191350
- A. Sheppard, Pharm. Tech. 22 (9), 72-74 (2010).
- (2010) Pharm. Tech. , vol.22 , Issue.9 , pp. 72-74
- Sheppard, A.¹

11
- 83455214565
- September
- Teissel, presentation at Sandoz Day Investors Event (September, 2008).
- (2008) Presentation at Sandoz Day Investors Event
- Teissel¹

12
- 83455214564
- Novartis Q4/full year 2010 results, January
- Novartis Q4/full year 2010 results, January 2011.
- (2011)

13
- 44449151539
- H. Grabowski, Nat. Rev. Drug Disc. 7, 479 (2008).
- (2008) Nat. Rev. Drug Disc. , vol.7 , pp. 479
- Grabowski, H.¹

14
- 0037250159
- M.D. Green et al., Ann. Oncol. 14, 29-35 (2003).
- (2003) Ann. Oncol. , vol.14 , pp. 29-35
- Green, M.D.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.